CSPC Pharmaceutical Group Limited has announced the approval of a clinical trial for its bispecific fusion protein drug, JMT106, in China. The approval was granted by the National Medical Products Administration of the People's Republic of China. JMT106 targets GPC3 and interferon receptors, aiming to kill tumor cells while activating immune regulation within the tumor microenvironment. It is specifically designed to address advanced solid tumors, including hepatocellular carcinoma, squamous cell carcinoma of the lung, and ovarian cancer. Previously, the U.S. Food and Drug Administration (FDA) approved the drug for clinical trials in the U.S. in January 2024. Preclinical studies have shown that JMT106 has significant anti-tumor effects and a strong safety profile, suggesting potential clinical development value.